Vanda Pharmaceuticals Inc. (VNDA) Expected to Announce Quarterly Sales of $51.43 Million

Wall Street brokerages expect Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) to post $51.43 million in sales for the current quarter, according to Zacks. Three analysts have made estimates for Vanda Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $49.70 million and the highest estimate coming in at $53.00 million. Vanda Pharmaceuticals reported sales of $44.28 million in the same quarter last year, which indicates a positive year-over-year growth rate of 16.1%. The business is scheduled to issue its next earnings report on Wednesday, February 13th.

According to Zacks, analysts expect that Vanda Pharmaceuticals will report full year sales of $191.47 million for the current year, with estimates ranging from $189.70 million to $193.00 million. For the next year, analysts forecast that the company will report sales of $253.30 million, with estimates ranging from $229.00 million to $292.00 million. Zacks’ sales calculations are a mean average based on a survey of research firms that that provide coverage for Vanda Pharmaceuticals.

Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its quarterly earnings results on Wednesday, November 7th. The biopharmaceutical company reported $0.13 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.05) by $0.18. The company had revenue of $49.13 million for the quarter, compared to the consensus estimate of $49.44 million. Vanda Pharmaceuticals had a net margin of 7.06% and a return on equity of 5.88%. The firm’s revenue was up 18.9% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.03) EPS.

Several research analysts recently commented on the stock. Stifel Nicolaus set a $36.00 price target on shares of Vanda Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, December 3rd. Jefferies Financial Group raised their price target on shares of Vanda Pharmaceuticals from $30.00 to $40.00 and gave the stock a “buy” rating in a research note on Tuesday. Oppenheimer reaffirmed a “buy” rating on shares of Vanda Pharmaceuticals in a research note on Monday, December 3rd. Citigroup raised their target price on shares of Vanda Pharmaceuticals from $31.00 to $47.00 and gave the company a “buy” rating in a research report on Friday. Finally, Zacks Investment Research raised shares of Vanda Pharmaceuticals from a “hold” rating to a “buy” rating and set a $23.00 target price on the stock in a research report on Tuesday, November 6th. Eight analysts have rated the stock with a buy rating and three have given a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $37.38.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Wells Fargo & Company MN increased its position in Vanda Pharmaceuticals by 396.9% during the 3rd quarter. Wells Fargo & Company MN now owns 652,305 shares of the biopharmaceutical company’s stock valued at $14,971,000 after purchasing an additional 521,040 shares during the period. Renaissance Technologies LLC grew its position in shares of Vanda Pharmaceuticals by 2.5% in the 2nd quarter. Renaissance Technologies LLC now owns 1,681,250 shares of the biopharmaceutical company’s stock worth $32,028,000 after buying an additional 41,200 shares during the last quarter. BlackRock Inc. grew its position in shares of Vanda Pharmaceuticals by 16.3% in the 2nd quarter. BlackRock Inc. now owns 4,960,924 shares of the biopharmaceutical company’s stock worth $94,506,000 after buying an additional 693,922 shares during the last quarter. Xact Kapitalforvaltning AB purchased a new position in shares of Vanda Pharmaceuticals in the 2nd quarter worth approximately $240,000. Finally, PNC Financial Services Group Inc. grew its position in shares of Vanda Pharmaceuticals by 25.0% in the 3rd quarter. PNC Financial Services Group Inc. now owns 279,485 shares of the biopharmaceutical company’s stock worth $6,414,000 after buying an additional 55,911 shares during the last quarter. 99.33% of the stock is currently owned by institutional investors and hedge funds.

VNDA stock traded down $1.82 during trading on Monday, hitting $27.60. The company had a trading volume of 652,062 shares, compared to its average volume of 771,460. The company has a market capitalization of $1.54 billion, a PE ratio of -78.86, a P/E/G ratio of 4.00 and a beta of 0.87. Vanda Pharmaceuticals has a 52-week low of $13.30 and a 52-week high of $33.44.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia.

Further Reading: What Factors Can Affect Return on Equity?

Get a free copy of the Zacks research report on Vanda Pharmaceuticals (VNDA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply